LM-030

• Description:

  LM-030 (BPR277) is a potent kallikrein-related peptidase 7 (KLK7) and epidermal elastase 2 (ELA2) inhibitor with IC50s of 6 nM and 55 nM, respectively (Example 4) [1]. LM-030 can be used for the study of Netherton syndrome[2].

• Product Name Alternative:

  BPR277

• UNSPSC:

  12352209

• Target:

  Elastase

• Type:

  Peptides

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/lm-030.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC[C@@H]([C@]1([H])N2C([C@@](CC[C@H]2O)([H])NC([C@@H](NC([C@H]([C@H](OC([C@](NC([C@@H](N(C1=O)C)CC3=CC=C(C=C3)O)=O)([H])[C@@H](C)CC)=O)C)NC([C@H](CCC(N)=O)NC(C(C)C)=O)=O)=O)CC(C)C)=O)=O)C

• Molecular Formula:

  C46H72N8O12

• Molecular Weight:

  929.11

• References & Citations:

  [1]Philipp Krastel, et al. Cyclic depsipeptides. WO2009024527A1|[2]Evgeniya Petrova, et al. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opinion on Orphan Drugs. 29 Dec 2020.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  Phase 1

• CAS Number:

  [1122484-55-2]